- Home
- SYBT vs ARWR Comparison
SYBT vs ARWR Comparison
Compare SYBT & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- ARWR
- Stock Information
- Founded
- SYBT 1904
- ARWR 2003
- Country
- SYBT United States
- ARWR United States
- Employees
- SYBT N/A
- ARWR N/A
- Industry
- SYBT Major Banks
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- ARWR Health Care
- Exchange
- SYBT Nasdaq
- ARWR Nasdaq
- Market Cap
- SYBT 2.2B
- ARWR 2.6B
- IPO Year
- SYBT N/A
- ARWR 1993
- Fundamental
- Price
- SYBT $72.94
- ARWR $19.90
- Analyst Decision
- SYBT Hold
- ARWR Buy
- Analyst Count
- SYBT 4
- ARWR 11
- Target Price
- SYBT $65.25
- ARWR $43.33
- AVG Volume (30 Days)
- SYBT 148.1K
- ARWR 2.5M
- Earning Date
- SYBT 01-22-2025
- ARWR 02-10-2025
- Dividend Yield
- SYBT 1.66%
- ARWR N/A
- EPS Growth
- SYBT 5.99
- ARWR N/A
- EPS
- SYBT 3.89
- ARWR N/A
- Revenue
- SYBT $342,545,000.00
- ARWR $2,500,000.00
- Revenue This Year
- SYBT N/A
- ARWR $3,336.78
- Revenue Next Year
- SYBT $5.94
- ARWR $124.29
- P/E Ratio
- SYBT $19.20
- ARWR N/A
- Revenue Growth
- SYBT 5.57
- ARWR N/A
- 52 Week Low
- SYBT $42.35
- ARWR $17.05
- 52 Week High
- SYBT $79.79
- ARWR $36.72
- Technical
- Relative Strength Index (RSI)
- SYBT 44.04
- ARWR 49.40
- Support Level
- SYBT $73.72
- ARWR $17.57
- Resistance Level
- SYBT $75.97
- ARWR $21.84
- Average True Range (ATR)
- SYBT 2.08
- ARWR 1.06
- MACD
- SYBT -0.29
- ARWR 0.11
- Stochastic Oscillator
- SYBT 24.14
- ARWR 54.57
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates a majority of its revenue from the Commercial Banking segment.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.